TY - JOUR
T1 - GABA dysfunction in the pathophysiology of tardive dyskinesia.
AU - Tamminga, C. A.
AU - Thaker, G. K.
AU - Chase, T. N.
PY - 1985
Y1 - 1985
N2 - Pharmacologic treatments which diminish central dopaminergic transmission improve symptoms of tardive dyskinesia (TD). These clinical data, supported by results from animal model studies, have provided a basis for the dopamine (DA) receptor hypersensitivity hypothesis of TD. Since its initial formulation, however, knowledge of the multiple effects of prolonged neuroleptic administration in mammalian CNS has greatly expanded. Clinical and animal model studies carried out independently now both suggest that GABA-mediated neuronal tracts of the basal ganglia are important, perhaps pivotal, in TD. Thus, we would extend the DA hypothesis of TD to include the idea that neuroleptic-induced DA receptor hypersensitivity in striatum results in GABA system hypofunction in striatal projection areas in those individuals who develop TD.
AB - Pharmacologic treatments which diminish central dopaminergic transmission improve symptoms of tardive dyskinesia (TD). These clinical data, supported by results from animal model studies, have provided a basis for the dopamine (DA) receptor hypersensitivity hypothesis of TD. Since its initial formulation, however, knowledge of the multiple effects of prolonged neuroleptic administration in mammalian CNS has greatly expanded. Clinical and animal model studies carried out independently now both suggest that GABA-mediated neuronal tracts of the basal ganglia are important, perhaps pivotal, in TD. Thus, we would extend the DA hypothesis of TD to include the idea that neuroleptic-induced DA receptor hypersensitivity in striatum results in GABA system hypofunction in striatal projection areas in those individuals who develop TD.
UR - http://www.scopus.com/inward/record.url?scp=0021935479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021935479&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-70140-5_16
DO - 10.1007/978-3-642-70140-5_16
M3 - Article
C2 - 2987903
AN - SCOPUS:0021935479
SN - 0179-8456
VL - 2
SP - 122
EP - 127
JO - Psychopharmacology. Supplementum
JF - Psychopharmacology. Supplementum
ER -